Antiviral drugs from basic discovery through clinical trials /
I tiakina i:
| Kaituhi rangatōpū: | |
|---|---|
| Ētahi atu kaituhi: | |
| Hōputu: | Tāhiko īPukapuka |
| Reo: | Ingarihi |
| I whakaputaina: |
Hoboken, N.J. :
Wiley,
c2011.
|
| Ngā marau: | |
| Urunga tuihono: | An electronic book accessible through the World Wide Web; click to view |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Rārangi ihirangi:
- pt. 1. Human immunodeficiency virus. section 1. HIV protease inhibitors ; section 2. HIV non-nucleoside reverse transcriptase inhibitors ; section 3. HIV nucleoside reverse transcriptase inhibitors ; section 4. HIV entry inhibitors ; section 5. HIV integrase inhibitors
- pt. 2. Hepatitis C virus. section 6. Protease inhibitors ; section 7. HCV polymerase nucleoside inhibitors ; section 8. Other HCV inhibitors
- pt. 3. Respiratory syncytial virus inhibitors
- pt. 4. Influenza, Hepatitis B, and Cytomegalovirus inhibitors.